- Mindset Pharma (MSET) releases strong confirmation of in vivo proof-of-concept across its entire new drug program portfolio
- Mindset has now identified a substantial pool of differentiated proprietary compounds with strong psychedelic effects confirmed in vivo
- Mindset has performed mouse head twitch assays and plans to conduct rat behavioural testing and rat drug discrimination testing
- Mindset Pharma is a drug development company focused on creating patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders
- Mindset Pharma Inc. (MSET) is in the grey and is trading at C$0.46 at 2:11 pm ET
Mindset Pharma (MSET) releases strong confirmation of in vivo proof-of-concept across its entire new drug program portfolio.
Mindset Pharma Inc. (MSET) has confirmed that the majority of its patent-pending compounds across four families of chemical scaffolds are exhibiting favourable effects in vivo in models established as having a high correlation to psychedelic effects in humans.
As a result of the promising data derived from Mindset's in vivo program, Mindset has now identified a substantial pool of differentiated proprietary compounds with strong psychedelic effects confirmed in vivo from which to select lead drug candidates to move to investigational new drug enabling studies.
To date, Mindset has tested 19 compounds in vivo, and 15 of such compounds have been shown to elicit the head twitch response in mice, which is a well-established behavioural marker of 5-HT2A agonism and is associated with producing a psychedelic effect in humans.
Achieving this high success rate in preclinical drug studies is reflective of Mindset's drug design and behavioural assessment capabilities.
Malik Slassi, Mindset's Senior VP of Innovation commented, "We are pleased to see such a consistently high rate of success from our in vivo screening program which has encompassed a range of rodent phenotypic screening to elucidate functional agonist properties at the 5-HT2A receptor studies."
"Mindset is well-positioned to select promising lead drug candidates to advance into IND-enabling studies from a strong pool of novel compounds," added Slassi.
To determine 5-HT2A receptor activity in vivo, Mindset has performed mouse head twitch assays, and plans to conduct rat behavioural testing and rat drug discrimination testing.
In addition to providing evidence of functional agonist properties at the 5-HT2A receptor, these tests also provide insights into potency, central nervous system penetration, oral bioavailability, duration of action, hallucinogenic properties, as well as some insights into safety.
Several of the compounds performed favourably on all of the currently tested metrics and are demonstrating promising physical-chemical property profiles for development as oral drugs for central nervous system disorders.
Additionally, Mindset has confirmed 5-HT2A activity by administering a selective 5-HT2A antagonist, M-100,907, and confirming that it blocks the mouse head twitch response.
James Lanthier, Chief Executive Officer of Mindset, added: "Once Mindset has completed in vivo screening of its compounds, the most promising candidate from each family will be selected as a lead and will then progress into IND-enabling studies."
Mindset Pharma is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs.
Mindset Pharma Inc. (MSET) is in the grey and is trading at C$0.46 at 2:11 pm ET.